Biomet Inc

Biomet — Imperial Capital (February 2010)

41 slides from Biomet's conference presentation, Feb 23, 2010

  1. Slide 1: Imperial Capital

    IMPERIAL CAPITAL FEBRUARY 23, 2010 DANIEL P. FLORIN SENIOR VICE PRESIDENT & CFO BIOMET, INC.

  2. Slide 2: Forward-Looking & Non-GAAP Financial Measures

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Forward-Looking & Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain forward-looking statements. They will be based upon management's current expectations and will involve ce

  3. Slide 3: Summary Business Overview

    Summary Business Overview 7,000+ team members 3,000+ sales representatives 900+ new products introduced FY 2000 – 2009 Operations in 50+ locations Products distributed in ~90 countries Eight strategic business units Company Profile Asia-Pac/ROW 11% United States 61% Europe 28% FY 2009 Revenues by Pr

  4. Slide 4: Orthopedic market segment sizes

    Orthopedic Reconstructive Devices $6,875 Dental Reconstructive Implants $740 Softgoods & Bracing $1,120 Sports Medicine $1,370 Bone Cements & Accessories $330 Spinal Products $6,865 O.R. Supplies $395 Fixation $3,395 Powered Surgical Equipment $245

  5. Slide 5: Global orthopedic market rankings

    #1 J & J/DePuy #2 Stryker/Howmedica #3 Zimmer/Centerpulse #4 Biomet #5 Synthes/Stratec #6 Smith & Nephew #4 Biomet

  6. Slide 6: Reconstructive market by joint

    Hips $2,620 Knees $3,890 Other $110 Shoulders $255

  7. Slide 7: Demographics

    Demographics 55- to 75-Year-Old U.S. Population Expected to Grow > 32% in 10 Years* Expansion of Target Population New Technologies to Treat Younger Patients Greater Activity Level & Improved Health of Elderly 54.8 Million 72.4 Million 2019 2009 *U.S. Census Bureau Projections

  8. Slide 8: Sales Growth by Product Segment at Constant Currency

    H1 FY ’10 Growth FY 2009 Growth FY 2008 Growth Recon Ex-Dental 8% 13% 12% 9% Dental 12% 13% (6%) (7%) Recon 9% 13% 9% 7% Fixation (11%) 0% 4% (1%) Spine (8%) 0% 7% 11% Other (1%) 6% 7% 8% Total 3% 10% 8% 6% Growth has rebounded from FY’07 levels, driven by core orthopedics business off-setting denta

  9. Slide 9: U.S. Orthopaedics Performance vs. Market

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Fended off significant competitive threat and re-established sales momentum U.S. Hip/Knee Growth Rates by Calendar Quarter* BIOMET 4.9% 7.5% 12.2% 12.1% 17.1% 9.0% 15.3% 11.3% 10.9% 10.4% 7.1% 9.5% MARKET 10.

  10. Slide 10: Biomet Europe Performance vs. Market

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Biomet Europe has grown substantially ahead of the market in 2008 and 2009 EU Market Share Positions CY 2007 vs. H1 CY 2009 Biomet Europe Performance vs. Market Data based on Company estimates 0.0% 2.0% 4.0%

  11. Slide 11: International Sales at Constant Currency Growth Rates

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i $- $50.0 $100.0 $150.0 $200.0 $250.0 $300.0 $137.1 $156.4 Primarily includes Canada, South America, Mexico and the Pacific Rim $- $50.0 $100.0 $150.0 $200.0 $250.0 $300.0 $205.0 $241.2 264.5 International Sal

  12. Slide 12: Reconstructive sales growth Q2'10

    Recon Sales Increased 6% Worldwide (C.C.) during Q2’10 Sales Increased 9% in the U.S.

  13. Slide 13: Hips: sales growth and new products

    Sales Grew 4% WW (C.C.) during Q2’10 Sales Increased 7% in the U.S. New Product Introductions E1 Antioxidant Infused Technology Plus Liners Echo Bi-Metric PPS Primary Stem Magnum Tri-Spike Acetabular Components Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma

  14. Slide 14: Hips: Key Products

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Hips Key Products M ² a-Magnum Acetabular System Taperloc Hip Stem E1 Antioxidant Infused Acetabular Bearings Exceed ABT ( A dvanced Bearing Technologies) Acetabular System* B T Hips *Not Available in U.S.

  15. Slide 15: Knees: sales growth and new products

    #4 U.S. Market Position Sales Grew 12% WW (C.C.) during Q2’10 Sales Increased 11% in the U.S. New Product Introductions E1 Antioxidant Infused Tibial Bearings Regenerex Press-Fit Tibia

  16. Slide 16: Knees: Key Products

    Key Products Vanguard Complete Knee System Oxford Partial Knee System

  17. Slide 17: Designed to Address the Entire Population

    Designed to Address the Entire Population 10 Femoral and 9 Tibial Sizes, completely interchangeable No Need to “ Correct ” Our Sizing for the Female Population No Peer-Reviewed Studies Associating Failure with Gender Biomet Knees = 98% Survivorship at 15 Years (Mensch, JS, Knee Morphology as a Guide

  18. Slide 18: Oxford Partial Knee long-term clinical results

    Only Free Floating Meniscal Bearing Partial Knee Approved in U.S. Excellent Long-Term Clinical Results 98% Success Rate at 10 Years 95% Success at 15 Years 92% Success at 20 Years

  19. Slide 19: Extremities: sales growth and key products

    Sales Grew 27% WW (C.C.) during Q2’10 Sales Increased 44% in the U.S. Key Products Comprehensive Primary and Reverse Shoulders Copeland Humeral Resurfacing Head T.E.S.S. (Total Evolutive Shoulder System)* *Not Available in U.S.

  20. Slide 20: Bone Cement: Key Products

    Key Products Cobalt G HV Bone Cement StageOne Cement Hip Spacer Molds StageOne Cement Knee Spacer Molds

  21. Slide 21: Osteobiologics: New Product Introductions

    New Product Introductions Bone Graft Convenience Kit Clotalyst System Coaxial Sprayer

  22. Slide 22: Dental sales: United States and International

    United States $740 International $2,060

  23. Slide 23: Biomet 3i: Industry Headwinds

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i (15%) (10%) (5%) 0% 5% 10% 15% 20% 25% CY 03 CY 04 CY 05 CY 06 CY 07 CY 08 CY 09E DENTAL IMPLANT MARKET (Constant Currency Sales Growth) QUARTERLY SALES GROWTH Constant-Currency, Based on Calendar Quarters (w

  24. Slide 24: Biomet 3i's New Introductions

    Biomet 3i’s New Introductions Encode Complete Zirconia Abutment Low Profile Conical Abutments The DU1000 Surgical Drill System ZiReal Art Ceramic Abutment

  25. Slide 25: Strategic Priority: Turn Around U.S. Trauma and Spine

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q Transaction Announced Transaction Closed Overhauled management team Fixed systems issues Created focused sales forces around spine and trauma

  26. Slide 26: U.S. Spine and Fixation Sales Growth Trends

    Stabilization and return to growth has been led by spine, but trauma turnaround lags; Fixation rates reflect above market craniomaxillofacial growth, more than offset by trauma, which is expected to show growth in fiscal 2011 By Fiscal Year, FY07-FY09 and Fiscal Quarter, Q1’10 – Q2’10 U.S. Spine and

  27. Slide 27: Fixation product categories

    Internal Fixation $2,110 Craniomaxillofacial Fixation $275 Electrical Stimulation $300 External Fixation $365 Growth Factors & Bone Substitute Materials $345

  28. Slide 28: Electrical stimulation technologies

    PEMF, DC, & CC Technologies FDA Acknowledged Mechanism of Action Involving Cascade of BMPs

  29. Slide 29: Fixation: Key Products

    Key Products OptiLock Proximal Humeral Plating System Phoenix Ankle Arthrodesis Nail Advanced Vision Foot Ring System

  30. Slide 30: Fixation: New Product Introductions

    New Product Introductions Custom TMJ Innovative Screw Delivery Device Neuro NexGen Next Gen Sternalock OnPoint 1.2mm Scope System Xpander (TMJ Jaw Motion Rehab System)

  31. Slide 31: Spine product categories

    Machined Allograft $520 Growth Factors & Bone Substitutes $1,075 Intervertebral Spacers $755 Electrical Stimulation $330 Motion Preservation $590 Plates, Rods, Screws $3,095 Vertebroplasty $500

  32. Slide 32: Spine: sales growth and new products

    Sales Grew 6% WW (C.C.) during Q2’10 Sales Increased 7% in the U.S. New Product Introductions Polaris Deformity Direct Vertebral Column Derotation System C-Tek MaxAn Cervical Plate System* *The C-Tek MaxAn Cervical Plate System incorporates technology developed by Gary K. Michelson, M.D.

  33. Slide 33: Sports Medicine: Procedure-Specific Arthroscopy Products

    Procedure-Specific Arthroscopy Products New Product Introductions ALLthread Knotless Suture Anchor ComposiTCP Interference Screw MicroMax FLEX Suture Anchor ZipTight Fixation System Sports Medicine Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i Sports Med

  34. Slide 34: Softgoods & Bracing: New Product Introductions

    #4 U.S. Market Position New Product Introductions Active Ankle CF Pro Aspen Contour LSO ( L umbar- S acral- O rthosis) Aspen Contour TLSO ( T horacic- L umbar- S acral O rthosis) Aspen QuickDraw RAP ( R igid A nterior P anel) Aspen TX Collar Aspen Vista Collar Biomet Cool Sport P.A.S.S. Performance

  35. Slide 35: Financial Highlights

    FINANCIAL HIGHLIGHTS

  36. Slide 36: Fiscal 2007–2009 Adjusted Operating Results

    Adjusted Net Income and Adjusted EBITDA reflect add-backs to GAAP results for non-cash amortization and stock comp expense, sponsor fees and other special charges Fiscal 2007 – 2009 Adjusted Operating Results Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i

  37. Slide 37: H1 Fiscal 2010 vs. H1 Fiscal 2009 Adjusted Operating Results

    Adjusted Net Income and Adjusted EBITDA reflect add-backs to GAAP results for non-cash amortization and stock comp expense, sponsor fees and other special charges H1 Fiscal 2010 vs. H1 Fiscal 2009 Adjusted Operating Results Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Med

  38. Slide 38: Balance Sheet & Cash Flow Data

    Biologics Bracing Microfixation Orthopaedics Osteobiologics Spine Sports Medicine Trauma 3i CAPITAL EXPENDITURES RECEIVABLE DAYS (1) INVENTORY TURNOVER, ADJUSTED (2) 88 91 76 71 73 0 20 40 60 80 100 FY 2006 FY 2007 FY 2008 FY 2009 11/30/2009 1.15 1.14 1.30 1.34 1.37 0 0.5 1 1.5 FY 2006 FY 2007 FY 20

  39. Slide 39: Operating Cash Flow Reconciled to Free Cash Flow

    In Millions, Unaudited GAAP Operating Cash Flow Reconciled to Free Cash Flow (FCF) & Unlevered FCF H1 Fiscal 2010 vs. H1 Fiscal 2009 Six Months Ended Six Months Ended November 30, 2009 November 30, 2008 Change Cash From Operations 81.1 $ 47.6 $ Capital expenditures (106.0) (92.9) Free Cash Flow (24.

  40. Slide 40: Flexible capital structure with significant liquidity

    Total Liquidity LTM EBITDA 7.7x 6.1x At Transaction Close Today LIQUIDITY NET DEBT LEVERAGE RATIOS (including projected run rate cost savings) Flexible capital structure with significant liquidity (1) As of November 30, 2009, as defined by our Credit Agreement (2) As defined by our Credit Agreement,

  41. Slide 41: Biomet Long-Term Track Record

    CONSOLIDATED SALES ($ in Millions) Extraordinary long-term track record of revenue and profitability growth through multiple industry and macro-economic cycles 10 Year CAGR 20 Year CAGR 11.7% 15.7% Biomet Long-Term Track Record SALES $0 $500 $1,000 $1,500 $2,000 $2,500 1987 1988 1989 1990 1991 1992

Biomet — Imperial Capital (February 2010) on 6ix